-
Effect of dapagliflozin on renal function and glucose and lipid
metabolism in patients with type 2 diabetes mellitus
- Ji Gaode, Jiang Lihua, Li Qun
-
2022, 28(11):
1579-1583.
DOI: 10.3760/cma.j.issn.1007-1245.2022.11.023
-
Asbtract
(
)
-
References |
Related Articles |
Metrics
Objective To observe the effect of dapagliflozin on renal function and glucose and
lipid metabolism in patients with type 2 diabetes mellitus (T2DM). Methods This was a prospective study. Eighty-six patients with T2DM admitted
to Jinan Second People's Hospital from July 2019 to July 2021 were selected as
the research objects. They were divided into a control group and an observation
group by the random number table method, with 43 cases in each group. The
control group had 25 males and 18 females, and they were (52.80±5.77)years old.
The obser vation group had 28 males and 15 females, and they were (53.19±5.82)years
old, All the patients were given conventional treatment, and the observation
group were treated with dapagliflozin on this basis. The clinical effects, the
levels of blood glucose [fasting blood glucose (FBG), 2h postprandial blood
glucose (2hPG), and glycosylated hemoglobin (HbA1c)], blood lipids
[total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol
(LDL-C), and high-density lipoprotein cholesterol (HDL-C)], oxidative stress
indicators [malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione
peroxidase (GSH-Px)], and renal function indicators [blood urea nitrogen (BUN),
serum creatinine (Scr), and urine microalbumin (UMA)], and the incidences of
adverse reactions were compared between these two groups. The independent-sample t test, paired t test, and χ2 test were applied. Results The treatment
response rate in the observation group was higher than that in the control
group [93.02% (40/43) vs. 74.42% (32/43)], with a statistical difference (χ2=5.161,P=0.023). After the treatment, the levels of FBG, 2hPG, HbA1c,
TC, TG, LDL-C, MDA, BUN, Scr, and UMA were (6.50±1.33) mmol/L, (8.35±1.44)
mmol/L, (6.01±0.54)%, (4.58±0.23) mmol/L, (1.41±0.22) mmol/L, (2.23±0.34)
mmol/L, (3.20±0.33) μmol/L, (6.33±1.07) mmol/L, (110.53±18.77) μmol/L, and
(10.34±3.21) mg/L in the observation group, which were significantly lower than
those in the control group [(7.39±1.50) mmol/L, (11.29±2.53) mmol/L,
(7.02±1.19)%, (5.23±0.70) mmol/L, (1.95±0.44) mmol/L, (3.31±0.52) mmol/ L,
(4.50±0.52) μmol/L, (9.86±2.55) mmol/L, (178.41±25.36) μmol/L, and (18.55±5.27)
mg/L], with statistical differences (t=2.911,
6.623, 5.068, 5.785, 7.198, 11.399, 13.842, 8.371, 14.108, and 8.725; all P<0.05). The levels of HDL-C and SOD
were (1.74±0.65) mmol/L and (43.96±8.22) U/ml in the observation group, which
were significantly higher than those in control group [(1.46±0.53) mmol/L and
(36.77±7.03) U/ml], with statistical differences (t=2.189 and 4.359; both P<0.05).
There was no statistical difference in GSH-Px between the two groups (t=0.206, P=0.837). There was no statistical difference in the incidence of
adverse reactions between the two groups [4.65% (2/43) vs. 9.30% (4/43);χ2=0.677, P=0.410]. Conclusion Dapagliflozin is
effective in the treatment of T2DM, and can effectively control blood glucose
level and improve lipid metabolism, oxidative stress, and renal function.